Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
in trials Drug class investigational GLP-1/GIP/glucagon triple receptor agonist Regulatory status NOT FDA-approved
Gastroparesis causes delayed gastric emptying, leading to severe discomfort and challenges in managing diabetes and obesity
(August 2015)
Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial)
Monitor your weight and appetite to assess your progress
Frequently Asked Questions How do clinicians evaluate whether GH-axis therapy is appropriate
US$ 24.36
US$ 22.35
US$ 24.77
US$ 26.30
US$ 24.78
